ICA-105665

Cat. No.:	HY-125469				
CAS No.:	2694728-63-5				
Molecular Formula:	C ₁₉ H ₁₅ F ₂ N ₃ O ₂				
Molecular Weight:	355.34				
Target:	Potassium Channel				
Pathway:	Membrane Transporter/Ion Channel				
Storage:	Powder	-20°C	3 years		
		4°C	2 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

®

MedChemExpress


SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg
Pre	Preparing Stock Solutions	1 mM	2.8142 mL	14.0710 mL	28.1421 mL
	5 mM	0.5628 mL	2.8142 mL	5.6284 mL	
		10 mM	0.2814 mL	1.4071 mL	2.8142 mL

BIOLOGICAL ACTIVITY			
Description	ICA-105665 (PF-04895162) is a potent and orally active neuronal Kv7.2/7.3 and Kv7.3/7.5 potassium channels opener. ICA- 105665 inhibits liver mitochondrial function and bile salt export protein (BSEP) transport (IC ₅₀ of 311 μM). ICA-105665 can penetrate the blood-brain barrier and has antiseizure effects ^{[1][2][3][4]} .		
IC ₅₀ & Target	Kv7.2/7.3 and Kv7.3/7.5 potassium channels ^{[1][2]}		
In Vitro	ICA-105665 (PF-04895162) does not display potent cytotoxic properties in THLE and HepG2 cell lines (IC ₅₀ ~192 μM and 130 μ M after 72 hours, respectively) or in human hepatocytes (AC ₅₀ for cell loss at 48 hours was >125 μM based on results in three assessments in two different human hepatocyte lots (LBN and HU4165) ^[1] . Mitochondrial respiratory reserve is compromised in human hepatocytes treated with ICA-105665 (PF-04895162) at concentrations >11 μM for 25 minutes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	For ICA-105665 (PF-04895162), in a 7-day rat toxicity study, dose-dependent alanine aminotransferase (ALT) elevations, potentially indicative of liver toxicity, were observed. However, no histological evidence of liver injury was identified, and		

Product Data Sheet

₩ O H



ALT elevations were not confirmed in a repeat 7-day study. Further, 28 day and 6 month toxicity studies in rats were negative for transaminase elevations and liver toxicity, and toxicity studies up to 9 months duration in cynomolgus monkeys were also negative^[2].

ICA-105665 (PF-04895162) has demonstrated broad spectrum antiseizure activity in multiple animal models including maximal electroshock, 6 Hz seizures, pentylenetetrazole, and electrical kindling at doses from <1 to 5 mg/kg^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Aleo MD, et al. Phase I study of PF-04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis. Pharmacol Res Perspect. 2019 Feb;7(1):e00467.

[2]. Generaux G, et al. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity. Pharmacol Res Perspect. 2019 Oct 9;7(6):e00523.

[3]. Kasteleijn-Nolst Trenité DG, et al. Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy. Epilepsia. 2013 Aug;54(8):1437-43.

[4]. Bialer M, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013 Jan;103(1):2-30.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA